Mind Medicine (MindMed) (MNMD) vs. The Competition Head to Head Contrast

Mind Medicine (MindMed) (NASDAQ:MNMDGetRating) is one of 49 public companies in the “Medicinals & botanicals” industry, but how does it compare to its peers? We will compare Mind Medicine (MindMed) to similar businesses based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Insider & Institutional Ownership

10.8% of Mind Medicine (MindMed) shares are owned by institutional investors. Comparatively, 16.3% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 23.1% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is owned for long-term growth.

Valuation and Earnings

This table compares Mind Medicine (MindMed) and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Mind Medicine (MindMed) N/A -$93.04 million -3.48
Mind Medicine (MindMed) Competitors $238.89 million -$88.70 million -7.78

Mind Medicine (MindMed)’s peers have higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.


This table compares Mind Medicine (MindMed) and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mind Medicine (MindMed) N/A -55.27% -51.10%
Mind Medicine (MindMed) Competitors -179.08% -256.98% -16.14%

Analyst Ratings

This is a summary of current ratings and price targets for Mind Medicine (MindMed) and its peers, as reported by MarketBeat.

Sell ​​Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mind Medicine (MindMed) 0 0 two 0 3.00
Mind Medicine (MindMed) Competitors 270 674 673 27 2.28

Mind Medicine (MindMed) currently has a consensus price target of 8.00, indicating a potential upside of 900.00%. As a group, “Medicinals & botanicals” companies have a potential upside of 109.47%. Given Mind Medicine (MindMed)’s stronger consensus rating and higher probable upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than its peers.

About Mind Medicine (MindMed) (GetRating)

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Receive News & Ratings for Mind Medicine (MindMed) Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mind Medicine (MindMed) and related companies with’s FREE daily email newsletter.


Related Articles

Leave a Reply

Your email address will not be published.

Back to top button